Prosecution Insights
Last updated: August 09, 2026
Application No. 18/305,192

STENT WITH COATED STRUTS

Final Rejection §DP
Filed
Apr 21, 2023
Priority
Sep 10, 2015 — provisional 62/216,573 +2 more
Examiner
DUKERT, BRIAN AINSLEY
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Boston Scientific Scimed Inc.
OA Round
2 (Final)
82%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants 82% — above average
82%
Career Allowance Rate
668 granted / 813 resolved
+12.2% vs TC avg
Moderate +11% lift
Without
With
+11.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
25 currently pending
Career history
835
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
34.8%
-5.2% vs TC avg
§102
28.0%
-12.0% vs TC avg
§112
24.3%
-15.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 813 resolved cases

Office Action

§DP
DETAILED ACTION The following is a final office action is response to communications received on 05/13/2026. Claims 1-19 are currently pending and addressed below. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant's arguments filed 05/13/2026 have been fully considered. As there was no Terminal Disclaimer filed, the double patenting rejection has not been overcome. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-9 & 13-18 of U.S. Patent No. 10,314,726. The elements of the instant application are to be found in the Patent and therefore are anticipated. Although the conflicting claims are not identical, they are not patentably distinct from each other because the Patent and the instant application all recite the same basic structure with a permutation of similar elements throughout. Regarding Claim 1, patent claim 1 recites the same limitations. Regarding Claims 2, 4 & 20, patent claim 4 recite the same limitations. Regarding Claim 3, patent claim 3 recites the same limitations. Regarding Claim 5, patent claim 5 recites the same limitations. Regarding Claim 6-12, patent claims 6-8 recite the same limitations. Regarding Claim 13, patent claim 9 recites the same limitations. Regarding Claim 14, patent claim 13 recites the same limitations. Regarding Claim 15, patent claim 14 recites the same limitations. Regarding Claim 16, patent claim 15 recites the same limitations. Regarding Claim 17, patent claim 16 recites the same limitations. Regarding Claim 18, patent claim 17 recites the same limitations. Regarding Claim 19, patent claim 18 recites the same limitations. Claims 1, 3, 5 & 13 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 2, 5, 8 & 12 of U.S. Patent No. 11,660,215. The elements of the instant application are to be found in the Patent and therefore are anticipated. Although the conflicting claims are not identical, they are not patentably distinct from each other because the Patent and the instant application all recite the same basic structure with a permutation of similar elements throughout. Regarding Claim 1, patent claim 1 recites the same limitations. Regarding Claim 3, patent claims 2 & 6 recite the same limitations. Regarding Claim 5, patent claim 8 recites the same limitations. Regarding Claim 13, patent claim 12 recites the same limitations. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN AINSLEY DUKERT whose telephone number is (571)270-3258. The examiner can normally be reached Mon-Fri 6am-4pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melanie Tyson can be reached at (571)272-9062. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN A DUKERT/Primary Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Apr 21, 2023
Application Filed
Dec 27, 2025
Non-Final Rejection (signed) — §DP
Feb 13, 2026
Non-Final Rejection mailed — §DP
May 13, 2026
Response Filed
Jul 31, 2026
Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12697222
IMPLANTS WITH GROOVE PATTERNS AND SOFT TISSUE ATTACHMENT FEATURES
2y 10m to grant Granted Aug 04, 2026
Patent 12690975
Hip joint method
4y 10m to grant Granted Jul 28, 2026
Patent 12690971
A REVISION-IMPLANT RECEIVER, AN IMPLANT ANCHOR AND METHOD OF USE THEREOF
3y 7m to grant Granted Jul 28, 2026
Patent 12690977
HUMERAL HEAD IMPLANT SYSTEM
3y 6m to grant Granted Jul 28, 2026
Patent 12685636
EXPANDABLE SHEATH FOR INTRODUCING AN ENDOVASCULAR DELIVERY DEVICE INTO A BODY
3y 8m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
82%
Grant Probability
93%
With Interview (+11.1%)
2y 7m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 813 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month